Clinical and molecular genetic study on two patients of the juvenile form of Pompe disease in China

OBJECTIVE: Glycogen-storage disease type II (GSD II, Pompe's disease) is an autosomal recessive disorder caused by a functional deficiency of acid alpha-glucosidase (GAA) that leads to glycogen accumulation within lysosomes in most tissues. The GAA gene is located to human chromosome 17q25 and...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Zhonghua er ke za zhi = Chinese journal of pediatrics. - 1960. - 45(2007), 10 vom: 23. Okt., Seite 760-4
1. Verfasser: Qiu, Jia-Jing (VerfasserIn)
Weitere Verfasser: Wei, Min, Zhang, Wei-Min, Shi, Hui-Ping
Format: Aufsatz
Sprache:Chinese
Veröffentlicht: 2007
Zugriff auf das übergeordnete Werk:Zhonghua er ke za zhi = Chinese journal of pediatrics
Schlagworte:English Abstract Journal Article Glycogen 9005-79-2 Glucan 1,4-alpha-Glucosidase EC 3.2.1.3
LEADER 01000caa a22002652 4500
001 NLM177015055
003 DE-627
005 20250209031305.0
007 tu
008 231223s2007 xx ||||| 00| ||chi c
028 5 2 |a pubmed25n0590.xml 
035 |a (DE-627)NLM177015055 
035 |a (NLM)18211760 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a chi 
100 1 |a Qiu, Jia-Jing  |e verfasserin  |4 aut 
245 1 0 |a Clinical and molecular genetic study on two patients of the juvenile form of Pompe disease in China 
264 1 |c 2007 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 22.12.2010 
500 |a Date Revised 16.03.2022 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a OBJECTIVE: Glycogen-storage disease type II (GSD II, Pompe's disease) is an autosomal recessive disorder caused by a functional deficiency of acid alpha-glucosidase (GAA) that leads to glycogen accumulation within lysosomes in most tissues. The GAA gene is located to human chromosome 17q25 and contains 20 exons, 19 of which are coding. Clinically, patients with the severe infantile form of GSD II have muscle weakness and cardiomyopathy eventually leading to death before the age of two years. Patients with the juvenile or the adult form of GSD II present with myopathy with a slow progression over several years or decades. A broad genetic heterogeneity has been described in GSD II in Europe, South Africa, USA, Japan and Korea, however, the investigation has not been performed in the patients from the mainland of China. In this study, clinical analysis and mutation detection were done on Chinese patients 
520 |a METHODS: Two unrelated juvenile patients with late onset GSD II (one boy, 3 years old and one girl, 9 years old) were included in the study with the informed consents. The diagnosis was confirmed by alpha-glucosidase determination in cultured fibroblasts. In addition, their clinical presentation, laboratory findings, electrophysiologic studies and muscle biopsy findings were analyzed in detail. Genomic DNA samples were extracted from fibroblasts of the probands, from peripheral blood of their parents and 50 unrelated, normal individuals. All the coding 19 exons and exon-intron boundaries of GAA were detected in the proband by polymerase chain reaction (PCR) and direct sequencing 
520 |a RESULTS: One patient presented decrease of muscle strength, limb-girdle hypotonia, the other patient presented reduced muscle volumes and respiratory problems. Both had increased CPK value, myopathic pattern on EMG; vacuoles on muscle biopsy, and deficiency of 1, 4-alpha-glucosidase activity. After 1 year follow up, the girl died after pneumonia at 10 years of age. One patient was found to be compound heretozygote for the novel mutation Arg702His, and the previously reported mutation Pro266Ser, which was reported in Korean population, with the late-onset phenotype. Two novel missense mutations Thr711Arg, Val723Met were found on the other patients 
520 |a CONCLUSIONS: Three mutations identified in the patient were new missense mutations causing late onset GSD II, which had not been reported elsewhere before 
650 4 |a English Abstract 
650 4 |a Journal Article 
650 7 |a Glycogen  |2 NLM 
650 7 |a 9005-79-2  |2 NLM 
650 7 |a Glucan 1,4-alpha-Glucosidase  |2 NLM 
650 7 |a EC 3.2.1.3  |2 NLM 
700 1 |a Wei, Min  |e verfasserin  |4 aut 
700 1 |a Zhang, Wei-Min  |e verfasserin  |4 aut 
700 1 |a Shi, Hui-Ping  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Zhonghua er ke za zhi = Chinese journal of pediatrics  |d 1960  |g 45(2007), 10 vom: 23. Okt., Seite 760-4  |w (DE-627)NLM136249191  |x 0578-1310  |7 nnns 
773 1 8 |g volume:45  |g year:2007  |g number:10  |g day:23  |g month:10  |g pages:760-4 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_50 
912 |a GBV_ILN_61 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_130 
912 |a GBV_ILN_227 
912 |a GBV_ILN_244 
912 |a GBV_ILN_285 
912 |a GBV_ILN_294 
912 |a GBV_ILN_350 
912 |a GBV_ILN_665 
912 |a GBV_ILN_813 
951 |a AR 
952 |d 45  |j 2007  |e 10  |b 23  |c 10  |h 760-4